I know this article by Sean O’Connor on the mistaken assumption in Bayh-Dole is six years old and I have discussed this issue previously, but since it is out there on the web, and as far as I know it hasn’t been retracted, I write another counterpoint to it. Perhaps the purpose served is to create a discussion, at least, with regard to the defects in Bayh-Dole.
The context of O’Connor’s analysis appears to be that university ownership of faculty inventions is a good thing, that Bayh-Dole set out to accomplish that, but screwed up with a mistaken assumption regarding an utterly basic requirement. Bayh-Dole could be fixed and so ensure that institutions rather than inventors control inventive work supported by public money.
Simply: folks drafting Bayh-Dole were mind-numbingly ignorant. Inventors are stupider. University ownership of inventions is virtuous. Bayh-Dole should serve virtue, not stupidity. And it can, but to make the law work, given its origin in ignorance, universities must repudiate academic freedom, tenure, and the freedom of research and publication. Then all will be well.
Sean O’Connor starts “Mistaken Assumptions: The Roots of Stanford v. Roche in Post-War Government Patent Policy” with this claim:
The Bayh-Dole Act of 1980 was built on a mistaken assumption that “contractors”—recipients of federal funding—were securing assignments of inventions from their employees.
O’Connor never identifies anyone involved in drafting Bayh-Dole who evidenced this mistaken assumption. Not Latker, not Bremer. The Bayh-Dole Act was drafted by Norman Latker at the NIH. I’ve talked with the person who typed the draft for Latker so it would not be traced to his government typewriter. Latker is recognized by “Bayh-Dole Central” as one of the “founding fathers” of Bayh-Dole. Another “founding father” is Howard Bremer, then patent counsel for the Wisconsin Alumni Research Foundation and head of the Society of University Patent Administrators (now called AUTM). Latker and Bremer previously had revived the NIH’s Institutional Patent Agreement program, which created master agreements between the NIH and universities concerning research inventions–but which excluded faculty investigators from being parties to that agreement.
The IPA program was used to circumvent both the Kennedy executive branch patent policy and the Public Health Service’s implementation of that policy. Under the IPA program, NIH-funded inventions could make their way as patent monopolies to private corporations with the assistance of university-affiliated patent brokers, who provided served as “middlemen” to cover the trail from public money to private monopoly. The private monopoly, it was argued, was necessary for there ever to be public benefit from such federally funded research. If university faculty discovered a cure for cancer–so the argument went–no company would bother to create a product based on that discovery unless it was first assured of a patent monopoly. Continue reading →